Bullfrog AI Holdings, Inc. Warrants

GAITHERSBURG, Md., March 08, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the availability of the recording for the recently held fireside chat. This enlightening session, hosted by RedChip Companies on March 5, 2024, featured BullFrog AI's CEO, Vin Singh, alongside Daniel R. Weinberger M.D., Director and CEO of the Lieber Institute for Brain Development (LIBD).

Related tickers: BFRG, BFRGW.

GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced February 21, 2024, the Underwriter’s decision to exercise their over-allotment option to purchase 218,382 shares of the Company’s common stock (the “Option Shares”), pursuant to the Underwriting Agreement, dated January 31, 2024, by and between BullFrog AI Holdings, Inc. and WallachBeth Capital, LLC as representative of the Underwriters (the “Underwriting Agreement”).

Related tickers: BFRG, BFRGW.